Terug
18
73
Dagbereik
€ 86,84
€ 88,36
52-Weeksbereik
€ 51,79
€ 101,40
Volume
551.679
50D / 200D Gem.
€ 90,26
/
€ 72,41
Vorige Slotkoers
€ 86,26
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 21,9 | 0,4 |
| P/B | 2,6 | 2,9 |
| ROE % | 12,3 | 3,7 |
| Net Margin % | 18,3 | 3,8 |
| Rev Growth 5Y % | 32,3 | 10,0 |
| D/E | 0,0 | 0,2 |
Belangrijkste Punten
Revenue grew 32,34% annually over 5 years — strong growth
Earnings grew 422,31% over the past year
ROE of 12,29% — decent returns on equity
Net margin of 18,30% shows strong profitability
Debt/Equity of 0,03 — conservative balance sheet
Generating 588,77M in free cash flow
Groei
Revenue Growth (5Y)
32,34%
Revenue (1Y)16,65%
Earnings (1Y)422,31%
FCF Growth (3Y)88,77%
Kwaliteit
Return on Equity
12,29%
ROIC7,67%
Net Margin18,30%
Op. Margin16,33%
Veiligheid
Debt / Equity
0,03
Current Ratio4,26
Interest Coverage0,00
Waardering
P/E Ratio
21,93
P/B Ratio2,58
EV/EBITDA23,73
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 16,65% | Revenue Growth (3Y) | 36,88% |
| Earnings Growth (1Y) | 422,31% | Earnings Growth (3Y) | 109,23% |
| Revenue Growth (5Y) | 32,34% | Earnings Growth (5Y) | 37,80% |
| Profitability | |||
| Revenue (TTM) | 2,94B | Net Income (TTM) | 537,90M |
| ROE | 12,29% | ROA | 10,14% |
| Gross Margin | 67,41% | Operating Margin | 16,33% |
| Net Margin | 18,30% | Free Cash Flow (TTM) | 588,77M |
| ROIC | 7,67% | FCF Growth (3Y) | 88,77% |
| Safety | |||
| Debt / Equity | 0,03 | Current Ratio | 4,26 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 21,93 | P/B Ratio | 2,58 |
| P/S Ratio | 4,01 | PEG Ratio | 0,05 |
| EV/EBITDA | 23,73 | Dividend Yield | 0,00% |
| Market Cap | 11,80B | Enterprise Value | 11,39B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,94B | 2,52B | 1,57B | 1,02B | 958,10M |
| Net Income | 537,90M | 102,98M | 122,87M | 190,17M | 149,19M |
| EPS (Diluted) | 3,92 | 0,75 | 1,07 | 1,85 | 1,44 |
| Gross Profit | 1,98B | 1,48B | 1,02B | 759,12M | 718,88M |
| Operating Income | 479,80M | 165,99M | 133,14M | 227,95M | 171,95M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5,30B | 5,25B | 5,09B | 2,08B | 1,96B |
| Total Liabilities | 729,51M | 1,07B | 1,09B | 229,75M | 215,88M |
| Shareholders' Equity | 4,57B | 4,18B | 4,00B | 1,85B | 1,74B |
| Total Debt | 118,66M | 537,19M | 520,40M | 6,01M | 0,0 |
| Cash & Equivalents | 526,16M | 784,44M | 467,29M | 150,47M | 193,07M |
| Current Assets | 2,13B | 2,18B | 1,92B | 983,34M | 864,52M |
| Current Liabilities | 498,50M | 855,91M | 392,35M | 159,20M | 140,16M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#981 of 1024
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#33 of 326
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026